Umifenovir is an indole derivative with broad-spectrum antiviral activity. It inhibits virus-mediated fusion with target membrane and blocks virus entry into target cells. It shows antiviral activity against many enveloped or non-enveloped RNA or DNA viruses with IC₅₀ values ranging from 0.41 to 16 uM. It (50 or 100 mg/kg/day) reduces mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Molecular dynamics and structural analysis show that Umifenovir may target SARS-CoV-2 spike glycoprotein and may block its trimerisation which will reduce cell adherence and virus entry.